Association of Serum 17 beta-Estradiol Concentration, Hormone Therapy, and Alveolar Crest Height in Postmenopausal Women

作者：Wang Youjin; LaMonte Michael J; Hovey Kathleen M; Mai Xiaodan; Tezal Mine; Millen Amy E; Ochs Balcom Heather M; Genco Robert J m; Barnabei Vanessa M; Wactawski Wende Jean^*

来源：Journal of Periodontology, 2015, 86(4): 595-605.

DOI：10.1902/jop.2015.140533

• osteoporosis
• periodontitis
• women's health

Background: Declines in endogenous estrogen levels after menopause can lead to systemic bone loss, including loss of oral bone and alveolar crest height (ACH). However, few studies have assessed both serum 17 beta-estradiol (E-2) and exogenous hormone therapy (HT) use in relation to oral bone loss.
Methods: This study examines the associations among serum E2, HT use, and ACH in 613 postmenopausal women from the Buffalo OsteoPerio study. Baseline ACH levels and 5-year ACH were assessed for groups according to E-2 level (undetectable, > 5.00 to <= 18.00, > 18.00 to <= 46.07, and > 46.07 pg/mL) and among HT use (never, ever) using analysis of variance and analysis of covariance. Logistic regression was used to analyze the association of ACH loss with serum E2 and HT use.
Results: In cross-sectional analyses, no association was found of serum E-2 with whole-mouth mean or worst-site ACH. However, history of HT use was associated with ACH. Women who had never used HT had more ACH loss assessed as a whole-mouth mean ACH (P = 0.01) and as worst-site ACH loss (P = 0.03). In logistic regression analyses of baseline ACH loss severity, HT never-users had two-fold higher odds of being in the severe ACH loss category compared to ever-users (odds ratio, 2.00; 95% confidence interval, 1.11 to 3.62). No association was observed of 5-year change in ACH with baseline serum E-2 or HT use.
Conclusion: Although this study did not detect an association with current serum E-2 level and ACH, HT use was found to be associated with less ACH loss in postmenopausal women.

• 出版日期2015-4